Reyhaneh Varshochian, Hosniyeh Hosseinzadeh, N. Gandomi, Faranak Tavassolian, F. Atyabi, R. Dinarvand
{"title":"利用脂质体和脂质纳米颗粒克服乳腺癌治疗中的挑战","authors":"Reyhaneh Varshochian, Hosniyeh Hosseinzadeh, N. Gandomi, Faranak Tavassolian, F. Atyabi, R. Dinarvand","doi":"10.2217/clp.14.48","DOIUrl":null,"url":null,"abstract":"Abstract Various lipid particulate drug delivery systems with liposomes as forefront have attracted increasing attention in cancer treatment, especially breast cancer therapy. Multidrug resistance and off-target cytotoxicity are among major obstacles faced by researchers in this area. To address these problems, various strategies, such as composition modifications, pegylation and attaching the targeting ligands, have been investigated. In this regard, a number of liposomal therapeutics could successfully reach the market and also several preclinical and clinical approaches are ongoing to upgrade lipid particles to multipotential carriers and potentiate their therapeutic efficacies. The current review is mainly concentrated on recent approaches in liposomal drug delivery systems intended for breast cancer therapy, and will have a glance at novel attributed studies based on other particulate lipid carriers.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"20 1","pages":"571 - 585"},"PeriodicalIF":0.0000,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Utilizing liposomes and lipid nanoparticles to overcome challenges in breast cancer treatment\",\"authors\":\"Reyhaneh Varshochian, Hosniyeh Hosseinzadeh, N. Gandomi, Faranak Tavassolian, F. Atyabi, R. Dinarvand\",\"doi\":\"10.2217/clp.14.48\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Various lipid particulate drug delivery systems with liposomes as forefront have attracted increasing attention in cancer treatment, especially breast cancer therapy. Multidrug resistance and off-target cytotoxicity are among major obstacles faced by researchers in this area. To address these problems, various strategies, such as composition modifications, pegylation and attaching the targeting ligands, have been investigated. In this regard, a number of liposomal therapeutics could successfully reach the market and also several preclinical and clinical approaches are ongoing to upgrade lipid particles to multipotential carriers and potentiate their therapeutic efficacies. The current review is mainly concentrated on recent approaches in liposomal drug delivery systems intended for breast cancer therapy, and will have a glance at novel attributed studies based on other particulate lipid carriers.\",\"PeriodicalId\":55252,\"journal\":{\"name\":\"Clinical Lipidology\",\"volume\":\"20 1\",\"pages\":\"571 - 585\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lipidology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/clp.14.48\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lipidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/clp.14.48","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}
Utilizing liposomes and lipid nanoparticles to overcome challenges in breast cancer treatment
Abstract Various lipid particulate drug delivery systems with liposomes as forefront have attracted increasing attention in cancer treatment, especially breast cancer therapy. Multidrug resistance and off-target cytotoxicity are among major obstacles faced by researchers in this area. To address these problems, various strategies, such as composition modifications, pegylation and attaching the targeting ligands, have been investigated. In this regard, a number of liposomal therapeutics could successfully reach the market and also several preclinical and clinical approaches are ongoing to upgrade lipid particles to multipotential carriers and potentiate their therapeutic efficacies. The current review is mainly concentrated on recent approaches in liposomal drug delivery systems intended for breast cancer therapy, and will have a glance at novel attributed studies based on other particulate lipid carriers.
期刊介绍：
The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
